| Hazard Information | Back Directory | [Uses]
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC)[1][2]. | [in vivo]
Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys[1].
Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts[2].
| Animal Model: | Cynomolgus monkey[1] | | Dosage: | 0.6, 6.0, and 60 mg/kg | | Administration: | Intravenous injection (i.v.) | | Result: | Induced > 100- fold increases in circulating concentrations of PDGF-AA. |
| Animal Model: | U118 glioma xenografts (CB17 SCID)[2] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.), twice per week. | | Result: | Produced 101% inhibition of tumor growth. |
| [IC 50]
PDGFRα | [References]
[1] Meina Liang, et al. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. AAPS J. 2020 Nov 18;23(1):4. DOI:10.1208/s12248-020-00523-3
[2] Naomi Laing, et al. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer. Mol Pharmacol. 2013 Jun;83(6):1247-56. DOI:10.1124/mol.112.084079 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|